Recent data reported an association between VEGF-A genotype of tumors and median overall survival as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer. In the present case we report a discordant VEGF-A genotype between tumor and normal tissue in a patient with a responsive hepatic lesion of chemoresistant breast cancer treated with bevacizumab and paclitaxel. Moreover, we show that, despite the very low VEGF-A protein expression, the neoplastic lesion was well vascularized and responded to bevacizumab therapy. The discordance of VEGF-A polymorphisms in tumor and germline DNA may suggest the importance of obtaining both information in order to predict a superior overall survival or a lower risk of hypertension in patients treated with taxanes and bevacizumab.
|Autori:||L. Coltelli;G. Allegrini;P. Orlandi;N. Giuntini;G. Alì;A. Fioravanti;E. Bona;M. T. Barletta;G. Fontanini;M. Del Tacca;R. Danesi;A. Falcone;G. Bocci|
|Titolo:||Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.|
|Anno del prodotto:||2009|
|Digital Object Identifier (DOI):||10.2217/pgs.09.55|
|Appare nelle tipologie:||1.1 Articolo in rivista|